Regeneron's strategy focuses on a broad pipeline across six therapeutic areas, with significant near-term data readouts ...

The US Food and Drug Administration (FDA) has granted Fast Track Designation to Complement Therapeutics’ CTx001, the ...

As we head into the 2026, let's take a look at biotech licensing deals and M&As that were inked in December 2025.

Novartis has significantly strengthened its neuroscience pipeline over recent years, topped by the $12bn acquisition of ...

Advancing investigational pre-clinical research of APL-9099 3, a potential one-time neonatal Fc receptor (FcRn) treatment ...

According to DelveInsight’s latest analysis, Nipocalimab is expected to capture meaningful market share across both prevalent ...

In an interview during ASH 2025, Ontada's Ira Zackson, MD explores the role of BTK inhibitors in chronic lymphocytic leukemia ...

ACCESS-AD launches at a pivotal time for Alzheimer’s disease management in Europe. Recent approvals of antibody-based disease-modifying therapies (DMTs) have expanded the treatment landscape, but ...

BURTON, MI, UNITED STATES, January 9, 2026 /EINPresswire.com/ -- Javelin Sciences, a pioneering certified biotechnology ...

The licensing agreement, which includes a big upfront payment of $650 million and milestone payments of up to $4.95 billion, ...

Preliminary Q4 2025 PEMGARDA® (pemivibart) net product revenue of $17.2 million, representing 25% growth year-over-year and 31% growth quarter-over-quarterPreliminary ending 2025 cash and cash ...

An update from Invivyd ( (IVVD) ) is now available.